Millenium: Strong buy
| eröffnet am: | 28.05.04 10:18 von: | geldschneider |
| neuester Beitrag: | 11.12.07 14:19 von: | Bereuhnix |
| Anzahl Beiträge: | 21 | |
| Leser gesamt: | 9838 | |
| davon Heute: | 1 | |
bewertet mit 0 Sternen |
||
|
|
||
28.05.04 10:18
#1
geldschneider
Millenium: Strong buy
Auch im Biotechsektor bewegen Analysten die Kurse: Die Deutsche Bank stufte Millennium Pharma (+6,1 Prozent auf 15,13 Dollar) auf "kaufen" herauf und nannte ein Kursziel von 19 Dollar. Die Experten erwarten positive Testergebnisse eines Lungenkrebspräparates.
28.05.04 10:28
#2
geldschneider
Velcade in Phase III ErgebnisPräsentation Asco mee
Millennium Announces VELCADE(R) (bortezomib) for Injection has Significantly Extended Survival in Phase III (APEX) Trial of Patients with Relapsed Multiple Myeloma -- Results to be presented at upcoming ASCO meeting --
Ergebnisse werden im Asco meeting vorgestellt!
CAMBRIDGE, Mass., May 17, 2004 /PRNewswire-FirstCall via COMTEX/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that in the final survival
endpoint analysis in the phase III confirmatory APEX study comparing patients
receiving VELCADE to those receiving high-dose dexamethasone, VELCADE produced a
statistically significant survival benefit. The study was designed to include
survival as a secondary endpoint and allowed crossover for patients experiencing
disease progression on high-dose dexamethasone to receive VELCADE. Both the
interim data and the final survival analysis from the APEX study will be
presented on Sunday, June 6, 2004 at the upcoming American Society of Clinical
Oncology (ASCO) meeting in New Orleans, LA.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO)
"We are extremely pleased and enthusiastic about the clear survival advantage
demonstrated in this trial," said David Schenkein, M.D., vice president,
clinical oncology development, Millennium. "This is the first randomized study
of a treatment in the relapsed multiple myeloma setting to show a survival
advantage over a current standard of care. Further, these data potentially
represent a significant opportunity to make an important difference in extending
survival for patients living with multiple myeloma."
The confirmatory phase III APEX trial included patients with relapsed or
refractory multiple myeloma whose disease had progressed after receiving one to
three previous therapies. The study was halted one year early in December of
2003 after a data monitoring committee concluded the findings of a pre-
specified interim analysis showed a statistically significant improvement in
time to disease progression -- the primary endpoint of the trial -- in patients
receiving VELCADE compared to patients receiving high-dose dexamethasone.
Patients were randomized to receive either VELCADE or high- dose dexamethasone,
a recognized standard of care in this setting. The trial enrolled more than 670
patients in 95 sites in the United States, Canada and Europe. The trial design
included a primary endpoint of time to disease progression and secondary
endpoints that included measurements of clinical benefit, safety and survival.
About VELCADE(R) (bortezomib) for Injection
VELCADE, the first of a new class of medicines called proteasome inhibitors, is
the first treatment in more than a decade to be approved for patients with
multiple myeloma -- a cancer of the blood. Millennium received approval from the
U.S. Food and Drug Administration (FDA) on May 13, 2003 to market VELCADE for
the treatment of multiple myeloma patients who have received at least two prior
therapies and have demonstrated disease progression on the last therapy. The
effectiveness of VELCADE is based on response rates. There are no controlled
trials demonstrating a clinical benefit such as an improvement in survival. On
April, 27, 2004, the European Commission granted marketing authorization for
VELCADE for the treatment of patients with multiple myeloma who have received at
least two prior therapies and have demonstrated disease progression on their
last therapy.
VELCADE is being co-developed by Millennium and Johnson & Johnson Pharmaceutical
Research & Development; Millennium is responsible for commercialization of
VELCADE in the U.S.; Ortho Biotech and Janssen-Cilag will be responsible for
commercialization in Europe and the rest of the world. Janssen Pharmaceutical
K.K. will be responsible for Japan.
VELCADE has a generally predictable, manageable safety profile (with appropriate
monitoring and, if necessary, dose modification). VELCADE is contraindicated in
patients with hypersensitivity to bortezomib, boron, or mannitol.
Risks associated with VELCADE therapy include new or worsening peripheral
neuropathy, orthostatic hypotension, congestive heart failure, gastrointestinal
adverse events, thrombocytopenia, and tumor lysis syndrome. Women of
childbearing potential should avoid becoming pregnant while being treated with
VELCADE.
In 228 patients who were treated with VELCADE(R) (bortezomib) 1.3 mg/m2/dose in
phase II studies, the most commonly reported adverse events were asthenic
conditions (65 percent), nausea (64 percent), diarrhea (51 percent), decreased
appetite including anorexia (43 percent), constipation (43 percent),
thrombocytopenia (43 percent), peripheral neuropathy (37 percent), pyrexia (36
percent), vomiting (36 percent), and anemia (32 percent). Fourteen percent of
patients experienced at least one episode of Grade 4 toxicity, with the most
common toxicities being thrombocytopenia (3 percent) and neutropenia (3
percent). A total of 113 (50 percent) of the 228 patients experienced Serious
Adverse Events (SAEs) during studies. The most commonly reported SAEs included
pyrexia (7 percent), pneumonia (7 percent), diarrhea (6 percent), vomiting (5
percent), dehydration (5 percent), and nausea (4 percent).
For more information about VELCADE clinical trials, patients and physicians can
contact the Millennium Medical Product Information Department at
1-(866)-VELCADE.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in
Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer
product, co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading
cardiovascular product, and has a robust clinical development pipeline of
product candidates. The Company's research, development and commercialization
activities are focused in three therapeutic areas: oncology, cardiovascular, and
inflammation. By applying its knowledge of the human genome, its understanding
of disease mechanisms, and its industrialized drug discovery platform,
Millennium is seeking to develop breakthrough products.
This press release contains "forward-looking statements," including statements
about our growth and future operating results, discovery and development of
products, potential acquisitions, strategic alliances and intellectual property.
Various important risks may cause the Company's actual results to differ
materially from the results indicated by these forward- looking statements,
including: adverse results in our drug discovery and clinical development
programs; failure to obtain patent protection for our discoveries; commercial
limitations imposed by patents owned or controlled by third parties; our
dependence upon strategic alliance partners to develop and commercialize
products and services based on our work; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from our
development efforts; the commercial success of INTEGRILIN and VELCADE; and the
requirement for substantial funding to conduct research and development and to
expand commercialization activities. For a further list and description of the
risks and uncertainties we face, see the reports we have filed with the
Securities and Exchange Commission. We disclaim any intention or obligation to
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Editor's Note: This release is available under the Media section on the
Company's website at www.millennium.com.
Contacts:
Kelly Lindenboom (media) Cynthia Clayton (investor)
(617) 679-7405 (617) 551-8607
SOURCE Millennium Pharmaceuticals, Inc.
CONTACT: Kelly Lindenboom (media), +1-617-679-7405, or Cynthia Clayton
(investor), +1-617-551-8607 both of Millennium Pharmaceuticals, Inc.
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
/Company News On-Call: http://www.prnewswire.com/comp/114562.html
URL: http://www.millennium.com
http://www.prnewswire.com
Copyright (C) 2004 PR Newswire. All rights reserved.
KEYWORD: Massachusetts
INDUSTRY KEYWORD: MTC
Ergebnisse werden im Asco meeting vorgestellt!
CAMBRIDGE, Mass., May 17, 2004 /PRNewswire-FirstCall via COMTEX/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that in the final survival
endpoint analysis in the phase III confirmatory APEX study comparing patients
receiving VELCADE to those receiving high-dose dexamethasone, VELCADE produced a
statistically significant survival benefit. The study was designed to include
survival as a secondary endpoint and allowed crossover for patients experiencing
disease progression on high-dose dexamethasone to receive VELCADE. Both the
interim data and the final survival analysis from the APEX study will be
presented on Sunday, June 6, 2004 at the upcoming American Society of Clinical
Oncology (ASCO) meeting in New Orleans, LA.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO)
"We are extremely pleased and enthusiastic about the clear survival advantage
demonstrated in this trial," said David Schenkein, M.D., vice president,
clinical oncology development, Millennium. "This is the first randomized study
of a treatment in the relapsed multiple myeloma setting to show a survival
advantage over a current standard of care. Further, these data potentially
represent a significant opportunity to make an important difference in extending
survival for patients living with multiple myeloma."
The confirmatory phase III APEX trial included patients with relapsed or
refractory multiple myeloma whose disease had progressed after receiving one to
three previous therapies. The study was halted one year early in December of
2003 after a data monitoring committee concluded the findings of a pre-
specified interim analysis showed a statistically significant improvement in
time to disease progression -- the primary endpoint of the trial -- in patients
receiving VELCADE compared to patients receiving high-dose dexamethasone.
Patients were randomized to receive either VELCADE or high- dose dexamethasone,
a recognized standard of care in this setting. The trial enrolled more than 670
patients in 95 sites in the United States, Canada and Europe. The trial design
included a primary endpoint of time to disease progression and secondary
endpoints that included measurements of clinical benefit, safety and survival.
About VELCADE(R) (bortezomib) for Injection
VELCADE, the first of a new class of medicines called proteasome inhibitors, is
the first treatment in more than a decade to be approved for patients with
multiple myeloma -- a cancer of the blood. Millennium received approval from the
U.S. Food and Drug Administration (FDA) on May 13, 2003 to market VELCADE for
the treatment of multiple myeloma patients who have received at least two prior
therapies and have demonstrated disease progression on the last therapy. The
effectiveness of VELCADE is based on response rates. There are no controlled
trials demonstrating a clinical benefit such as an improvement in survival. On
April, 27, 2004, the European Commission granted marketing authorization for
VELCADE for the treatment of patients with multiple myeloma who have received at
least two prior therapies and have demonstrated disease progression on their
last therapy.
VELCADE is being co-developed by Millennium and Johnson & Johnson Pharmaceutical
Research & Development; Millennium is responsible for commercialization of
VELCADE in the U.S.; Ortho Biotech and Janssen-Cilag will be responsible for
commercialization in Europe and the rest of the world. Janssen Pharmaceutical
K.K. will be responsible for Japan.
VELCADE has a generally predictable, manageable safety profile (with appropriate
monitoring and, if necessary, dose modification). VELCADE is contraindicated in
patients with hypersensitivity to bortezomib, boron, or mannitol.
Risks associated with VELCADE therapy include new or worsening peripheral
neuropathy, orthostatic hypotension, congestive heart failure, gastrointestinal
adverse events, thrombocytopenia, and tumor lysis syndrome. Women of
childbearing potential should avoid becoming pregnant while being treated with
VELCADE.
In 228 patients who were treated with VELCADE(R) (bortezomib) 1.3 mg/m2/dose in
phase II studies, the most commonly reported adverse events were asthenic
conditions (65 percent), nausea (64 percent), diarrhea (51 percent), decreased
appetite including anorexia (43 percent), constipation (43 percent),
thrombocytopenia (43 percent), peripheral neuropathy (37 percent), pyrexia (36
percent), vomiting (36 percent), and anemia (32 percent). Fourteen percent of
patients experienced at least one episode of Grade 4 toxicity, with the most
common toxicities being thrombocytopenia (3 percent) and neutropenia (3
percent). A total of 113 (50 percent) of the 228 patients experienced Serious
Adverse Events (SAEs) during studies. The most commonly reported SAEs included
pyrexia (7 percent), pneumonia (7 percent), diarrhea (6 percent), vomiting (5
percent), dehydration (5 percent), and nausea (4 percent).
For more information about VELCADE clinical trials, patients and physicians can
contact the Millennium Medical Product Information Department at
1-(866)-VELCADE.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in
Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer
product, co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading
cardiovascular product, and has a robust clinical development pipeline of
product candidates. The Company's research, development and commercialization
activities are focused in three therapeutic areas: oncology, cardiovascular, and
inflammation. By applying its knowledge of the human genome, its understanding
of disease mechanisms, and its industrialized drug discovery platform,
Millennium is seeking to develop breakthrough products.
This press release contains "forward-looking statements," including statements
about our growth and future operating results, discovery and development of
products, potential acquisitions, strategic alliances and intellectual property.
Various important risks may cause the Company's actual results to differ
materially from the results indicated by these forward- looking statements,
including: adverse results in our drug discovery and clinical development
programs; failure to obtain patent protection for our discoveries; commercial
limitations imposed by patents owned or controlled by third parties; our
dependence upon strategic alliance partners to develop and commercialize
products and services based on our work; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from our
development efforts; the commercial success of INTEGRILIN and VELCADE; and the
requirement for substantial funding to conduct research and development and to
expand commercialization activities. For a further list and description of the
risks and uncertainties we face, see the reports we have filed with the
Securities and Exchange Commission. We disclaim any intention or obligation to
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Editor's Note: This release is available under the Media section on the
Company's website at www.millennium.com.
Contacts:
Kelly Lindenboom (media) Cynthia Clayton (investor)
(617) 679-7405 (617) 551-8607
SOURCE Millennium Pharmaceuticals, Inc.
CONTACT: Kelly Lindenboom (media), +1-617-679-7405, or Cynthia Clayton
(investor), +1-617-551-8607 both of Millennium Pharmaceuticals, Inc.
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
/Company News On-Call: http://www.prnewswire.com/comp/114562.html
URL: http://www.millennium.com
http://www.prnewswire.com
Copyright (C) 2004 PR Newswire. All rights reserved.
KEYWORD: Massachusetts
INDUSTRY KEYWORD: MTC
08.06.04 13:31
#3
geldschneider
Themean auf der Asco von MLnm
Abstracts search for Millenium returned 10 result(s).
1. Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips.
Home > Meetings & Education > Abstracts >
Meeting: 2004 ASCO Annual Meeting Abstract No: 503 First Author: L. Pusztai
Category: Metastatic Breast Cancer
2. Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC).
Home > Meetings & Education > Abstracts >
Meeting: 2004 ASCO Annual Meeting Abstract No: 4089 First Author: S. Hegewisch-Becker
Category: Hepatobiliary Cancer
3. Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Home > Meetings & Education > Abstracts >
Meeting: 2004 ASCO Annual Meeting Abstract No: 4654 First Author: R. Dreicer
Category: Prostate Cancer
http://www.asco.org/ac/1,1003,_12-002546,00.asp?Search=Millenium
1. Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips.
Home > Meetings & Education > Abstracts >
Meeting: 2004 ASCO Annual Meeting Abstract No: 503 First Author: L. Pusztai
Category: Metastatic Breast Cancer
2. Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC).
Home > Meetings & Education > Abstracts >
Meeting: 2004 ASCO Annual Meeting Abstract No: 4089 First Author: S. Hegewisch-Becker
Category: Hepatobiliary Cancer
3. Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Home > Meetings & Education > Abstracts >
Meeting: 2004 ASCO Annual Meeting Abstract No: 4654 First Author: R. Dreicer
Category: Prostate Cancer
http://www.asco.org/ac/1,1003,_12-002546,00.asp?Search=Millenium
15.06.04 11:09
#4
geldschneider
Millenium bei Ariva nicht bekannt!
Bei Eingabe unter Wertpapier kommen andere Millenium, aber dieses nicht!
31.01.05 10:42
#5
bilal61191
langsam
müsss man sich mlnm ins depot holen ich habe zu 7,25 mich eingedeckt demnächst laufen die wider auf 9 euro zu das ist bei mlnm sicher:))
31.01.05 21:09
#6
Slash
derzeit aber noch im Abwärtstrend.
Aber es sieht nach einer leichten Bodenbildung aus.
Gruß slash
Gruß slash
02.02.05 12:04
#7
sertralin19
aber hoffentlich nicht mehr lange ...
habe meine Position zu 7,20 verdoppelt. MLMN dreht sicher bald wieder nach oben. Das ist immer so, kurz nachdem der "Aktionär" vor dem Wiedereinstieg gewarnt hat. Die empfehlen MLMN immer dann, wenn sich die Aktie bereits um 50 oder 100 % vom Tiefstand erholt hat. Nach jedem Einbruch raten sie dann von weiteren Engagements ab, genau in dem Moment, in dem ein Kauf optimal wäre, um vom nächsten Aufwärtsschub zu profitieren. MLNM, auf meiner Liste zur Zeit ein klares STRONG BUY!
Gruß
sertralin19
habe meine Position zu 7,20 verdoppelt. MLMN dreht sicher bald wieder nach oben. Das ist immer so, kurz nachdem der "Aktionär" vor dem Wiedereinstieg gewarnt hat. Die empfehlen MLMN immer dann, wenn sich die Aktie bereits um 50 oder 100 % vom Tiefstand erholt hat. Nach jedem Einbruch raten sie dann von weiteren Engagements ab, genau in dem Moment, in dem ein Kauf optimal wäre, um vom nächsten Aufwärtsschub zu profitieren. MLNM, auf meiner Liste zur Zeit ein klares STRONG BUY!
Gruß
sertralin19
02.02.05 12:33
#8
bradetti
Millennium - mein Liebling!
Hallo Sertralin19!
Ich hatte MLMN seit 2001. Habe sie letztes Jahr aber bei 10€ Kurs verkauft (ich gebe zu: schweren Herzens)! Kann nur sagen: Glück gehabt. Beobachte sie aber immer noch ständig.
Grundsätzlich könntest Du mit Deiner Meinung Recht haben, aber um den Abwärtstrend zu durchbrechen (erst dann sollte man ja investieren) muss die Aktie schon mal ganz paar Prozente zulegen, die man halt verpasst, aber charttechnisch ist das bissel sicherer!
Denn in der jetztigen Situation fällt mir nur ein: "Greife nie in ein fallendes Messer!"
Wenn es nicht weiter runter geht, freue ich mich natürlich für Dich!
Ich hatte MLMN seit 2001. Habe sie letztes Jahr aber bei 10€ Kurs verkauft (ich gebe zu: schweren Herzens)! Kann nur sagen: Glück gehabt. Beobachte sie aber immer noch ständig.
Grundsätzlich könntest Du mit Deiner Meinung Recht haben, aber um den Abwärtstrend zu durchbrechen (erst dann sollte man ja investieren) muss die Aktie schon mal ganz paar Prozente zulegen, die man halt verpasst, aber charttechnisch ist das bissel sicherer!
Denn in der jetztigen Situation fällt mir nur ein: "Greife nie in ein fallendes Messer!"
Wenn es nicht weiter runter geht, freue ich mich natürlich für Dich!
02.02.05 23:05
#9
bilal61191
mlnm
ich denke die werd noch mal die 6,50 marke testen und dann drehen hoffe ich
mal sehen was nächster woche so passiert
mal sehen was nächster woche so passiert
11.02.05 19:33
#10
Slash
Das nenne ich mal einen Treffer.
Gut, nicht ganz. Bis 6,3€ gings ja kurz runter.
M.e. wird es auch noch einmal etwas tiefer gehen, aber dann...
Gruß slash
M.e. wird es auch noch einmal etwas tiefer gehen, aber dann...
Gruß slash
06.03.05 16:11
#11
Slash
nächste Woche mal genauer hinsehen
Unter 6€ könnte man einsteigen und dann abwarten.
Wohl gemerkt nur meine Meinung.
Gruß slash
Wohl gemerkt nur meine Meinung.
Gruß slash
07.03.05 19:35
#12
kamm
warten ein bischen mehr..
Am 29.März erwarten wir news über Velcade, und hoffen "good ones".In diesem Fall soll die Aktie bei 11$ steigen.Auch am 28.April ist die Ergebnis Präsentation...warten wir mal.
tekamel.com
tekamel.com
18.03.05 22:41
#13
Lenmat
Die 6 scheint zu halten,
jetzt noch positive Nachrichten und es geht wieder aufwärts für MLNM eines meiner Sorgenkinder.
26.04.05 11:41
#15
sertralin19
Wenn das kein Traum von einem Doppelboden ist ...
&save_presets=0&go=upper&a=900625&b=0&banner_ref=HASH(0x9e8f8ec)&zeitraum=8&ind_volume=ON&zoom.x=0&zeitbis=&bname=&bis=1114508124.98505&cookies=HASH(0x96640c8)&req_host=ARRAY(0x9e8aac8)&zeitvon=0&von=0)
... dann weiß ich auch nicht, was Charttechnik überhaupt für eine Bedeutung haben soll. Und das beste: Die derzeitige Trendwende erfolgt im $-Chart (hier nur in Euro verfügbar) exakt auf dem 2000 begonnenen langfristigen Aufwärtstrend. Kurs könnte m.E. jetzt schnell und deutlich nach oben ziehen. Ich bin auch sicher nicht der einzige, der dieses verlockende Muster erkennt. Die guten News - was auch immer - werden dann bald folgen. Ist ja meistens so. Erst die Bewegung - die Begründung danach.
Gruß
sertralin19
... dann weiß ich auch nicht, was Charttechnik überhaupt für eine Bedeutung haben soll. Und das beste: Die derzeitige Trendwende erfolgt im $-Chart (hier nur in Euro verfügbar) exakt auf dem 2000 begonnenen langfristigen Aufwärtstrend. Kurs könnte m.E. jetzt schnell und deutlich nach oben ziehen. Ich bin auch sicher nicht der einzige, der dieses verlockende Muster erkennt. Die guten News - was auch immer - werden dann bald folgen. Ist ja meistens so. Erst die Bewegung - die Begründung danach.
Gruß
sertralin19
17.06.05 17:30
#16
sertralin19
15 % Plus in New York unter Hammervolumen
... die "Doppelbodenthese" scheint aufzugehen!
Go!
... die "Doppelbodenthese" scheint aufzugehen!
Go!
06.11.07 21:08
#18
smallblock
na endlich mal
bin schon länger drin, aber endlich auch mal ne aufwärtsbewegung.Was meint ihr?Charttechniker anwesend?
08.11.07 18:53
#19
sertralin19
Da habe ich auch lang drauf gewartet ...
... und ich denke, dass nach der langen Konsolidierung jetzt eine nachhaltige Aufwärtsbewegung ansteht. Erstes KZ ca. 14 $, wenns da durch geht, sind auch schnell 20 $ drin.Langfristig sicher auch mehr. Velcade entwickelt sich besser als angenommen und wird scheints zum Gold-Standard bei mult. Lymphomen. Test bei anderen Krebsarten laufen gut, die Pipeline bietet auch sonst noch einiges. Meine Einschätzung: Vergessener Bio-Bolide startet zur Aufholjagd!
Gruß
sertralin19
... und ich denke, dass nach der langen Konsolidierung jetzt eine nachhaltige Aufwärtsbewegung ansteht. Erstes KZ ca. 14 $, wenns da durch geht, sind auch schnell 20 $ drin.Langfristig sicher auch mehr. Velcade entwickelt sich besser als angenommen und wird scheints zum Gold-Standard bei mult. Lymphomen. Test bei anderen Krebsarten laufen gut, die Pipeline bietet auch sonst noch einiges. Meine Einschätzung: Vergessener Bio-Bolide startet zur Aufholjagd!
Gruß
sertralin19
11.12.07 14:16
#20
smallblock
hört sich alles sehr gut an
weitere positive nachrichten könnten für enorme kurssprünge sorgen.
Freu mich schon jetzt auf 2008, the real Millenium !
Freu mich schon jetzt auf 2008, the real Millenium !
11.12.07 14:19
#21
Bereuhnix
Wieder mal lauter Laien die von der
Firma Null Ahnung haben.
lol
Kauf mal fleissig, ich kenne ein Mmedikament duch eine Kollegin....
lol
Kauf mal fleissig, ich kenne ein Mmedikament duch eine Kollegin....